Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00537810 · ClinicalTrials.gov registry record · Phase 4

Treatment of Binge Eating in Obese Patients in Primary Care

A Phase 4 study, sponsored by Yale University.

Completed
Registry status
Phase 4
Development phase
104
Enrollment target

NCT00537810: Completed Phase 4 study, sponsored by Yale University.

NCT00537810 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 104 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00537810, a Phase 4 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 4
Development phase
104 participants
Enrollment target

Study Summary

This study will test the effectiveness of two empirically-supported but distinct treatments for recurrent binge eating in obese patients: 1) Cognitive Behavior Therapy, using a pure self-help approach and 2) sibutramine, an anti-obesity medication also found to have efficacy for binge eating. Self-help Cognitive Behavior Therapy and sibutramine will be administered alone and in combination in a primary care setting.

Primary Outcome

Remission from binge eating (zero binge episodes during previous 28 days)

Interventions

  • DRUG Placebo
  • DRUG Sibutramine
  • BEHAVIORAL Self-help CBT + Sibutramine
  • BEHAVIORAL Self-help CBT + Placebo

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2007-09
Est. Completion 2012-10
Phase Phase 4
Yale University

1,492 total trials

What the finished NCT00537810 record still lists

NCT00537810 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT00537810 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00537810 about?

NCT00537810 is a clinical study titled "Treatment of Binge Eating in Obese Patients in Primary Care". This study will test the effectiveness of two empirically-supported but distinct treatments for recurrent binge eating in obese patients: 1) Cognitive Behavior Therapy, using a pure self-help approach and 2) sibutramine, an anti-obesity medication also found to have efficacy for binge eating. Self-h...

What is the current status of trial NCT00537810?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2007-09. Estimated completion is 2012-10.

What interventions are being tested in trial NCT00537810?

The interventions under investigation include: Placebo (DRUG), Sibutramine (DRUG), Self-help CBT + Sibutramine (BEHAVIORAL), Self-help CBT + Placebo (BEHAVIORAL).

Who is sponsoring clinical trial NCT00537810?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00537810's enrollment target sits among peer trials

104 754th of 2000 higher than 1,241 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00537810, the US trial registry maintained by the National Library of Medicine. NCT00537810 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.